Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial (Q47701722)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 July 2016

Language	Label	Description	Also known as
English	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial	scientific article published on 7 July 2016

Statements

scholarly article

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

chemoradiotherapy

0 references

phase III clinical trial

0 references

radiation therapy

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

endometrial cancer

1 reference

based on heuristic

inferred from title

11

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Stephanie M de Boer

object named as

Stephanie M de Boer

1

0 references

Carien L Creutzberg

object named as

Carien L Creutzberg

20

0 references

object named as

Hein Putter

19

0 references

Christine Haie-Meder

6

object named as

Christine Haie-Meder

1 reference

Europe PubMed Central

4 February 2018

Linda Mileshkin

3

object named as

Linda Mileshkin

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Dionyssios Katsaros

4

object named as

Dionyssios Katsaros

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

5

object named as

Paul Bessette

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Petronella Beatrix Ottevanger

7

object named as

Petronella B Ottevanger

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Jonathan A Ledermann

8

object named as

Jonathan A Ledermann

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

9

object named as

Pearly Khaw

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Henry C Kitchener

13

object named as

Henry C Kitchener

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

14

object named as

Hans W Nijman

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

16

object named as

Remi A Nout

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Karen W Verhoeven-Adema

17

object named as

Karen W Verhoeven-Adema

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

PORTEC study group

21

object named as

PORTEC study group

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

author name string

Melanie E Powell

2

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Alessandro Colombo

10

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Marie-Helene Baron

12

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Roy F Kruitwagen

15

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Vincent T Smit

18

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

publication date

7 July 2016

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Lancet Oncology Commission

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

17

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

8

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

1114-1126

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930120-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30120-6

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/27397040

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47701722&oldid=2166203319"